Showing results (21-30 of 102) with videos related to
Sort By:
Pageof 11
Expert Opinion on Drug Delivery|May 17, 2018
Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE®-RL)Stanley Cohen, Piotr A Klimiuk, Tillmann Krahnke, et al.The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|August 24, 2018
Three-Dimensional Cellular Raman Analysis: Evidence of Highly Ordered Lipids Within Cell NucleiBhagavathi Ramamurthy, Stanley Cohen, Mark Canales, et al.Cell Cycle (Georgetown, Tex.)|May 25, 2006
Multiple initiation sites within the human ribosomal RNA geneFrederick D Coffman, Mai He, Mai-Ling Diaz, et al.Cell Cycle (Georgetown, Tex.)|August 6, 2005
DNA replication initiates at different sites in early and late S phase within human ribosomal RNA genesFrederick D Coffman, Mai He, Mai-Ling Diaz, et al.Expert Opinion on Biological Therapy|November 6, 2024
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn's disease, and chronic plaque psoriasisStanley Cohen, Shaun Bender, Amy Shaberman, et al.Analytical Cellular Pathology (Amsterdam)|October 13, 2011
Biophysical profiling of tumor cell linesFrederick Coffman, Rachid Hamid, Marion C Cohen, et al.Clinical Rheumatology|September 23, 2020
Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritisGerd Burmester, Edit Drescher, Pawel Hrycaj, et al.British Journal of Clinical Pharmacology|March 18, 2010
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustmentStanley Cohen, Samuel H Zwillich, Vincent Chow, et al.Academic Pathology|October 27, 2018
What Advice Current Pathology Chairs Seek From Former ChairsDavid N Bailey, Stanley Cohen, Avrum Gotlieb, et al.Future Oncology (London, England)|November 14, 2019
Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseasesWojciech Jurczak, Stanley Cohen, Timothy M Illidge, et al.Pageof 11